Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic

Autores da FMUP
Participantes de fora da FMUP
- Lopes-Conceicao, L
- Ferreira, A
- Oliveira, J
- Braga, I
- Morais, S
- Pacheco-Figueiredo, L
- Ruano, L.
- Cruz, VT
- Ferreira, S.
Unidades de investigação
Abstract
Background: Androgen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis. Patients and methods: Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes. Results: Mean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, P < 0.001). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, P for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, P for interaction = 0.044). Conclusions: ADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown.
Dados da publicação
- ISSN/ISSNe:
- 2059-7029, 2059-7029
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
ESMO Open Elsevier BV
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Filiações não disponíveis
Keywords
- prostate cancer; neurocognitive disorders; longitudinal studies; hormones; hormone substitutes; hormone antagonists/analogues and derivatives; COVID-19; complications
Campos de estudo
Proyectos asociados
Quality of Life after Transient Ischemic Attack
Investigador Principal: Andreia Filipa Gomes da Costa
Estudo Clínico Académico (Transient) . 2021
The role of hepatocyte apoptosis markers in predicting the histological and serological activity in steatohepatitis
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2021
Healthcare use among cancer patients and their partners in different phases of the cancer pathway
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2021
Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2020
RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2019
Citar a publicação
Araujo N,Costa A,Lopes L,Ferreira A,Carneiro F,Oliveira J,Braga I,Morais S,Pacheco L,Ruano L,Cruz VT,Ferreira S,Lunet N. Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic. ESMO Open. 2022. 5. (2):100448. IF:7,300. (1).